Interleukin preparations

Cytokines as the basis of therapy

To understand the mechanism of action of this drug group, it is necessary to recall the basic principles of the immune system. Interleukin preparations belong to the broad class of cytokines. Under natural conditions, endogenous cytokines are produced by the body itself and serve as universal regulators. They transmit signals between cells, coordinating both the immune response against foreign agents and hematopoiesis (blood formation). The creation of recombinant analogues of these substances has allowed pharmacologists to directly intervene in immunological reactions. By administering such drugs exogenously, we can purposefully enhance the proliferation of required cells, activate their protective functions, or restore impaired hematopoiesis.

Aldesleukin: a recombinant analogue of IL-2

One of the key representatives of the group is aldesleukin. By definition, this drug is an exact recombinant analogue of endogenous interleukin-2 (IL-2). Its pharmacodynamics is based on the ability to specifically bind to IL-2 receptors located on the membranes of target cells.

Upon receptor binding, a complex cascade of reactions is triggered, leading to the following effects:

• A powerful stimulation of differentiation and proliferation processes of T-lymphocytes occurs.
• The growth and development of other cell populations whose viability directly depends on the presence of interleukin-2 are activated.
• The cytotoxicity of lymphocytes and specialized killer cells (NK cells) is significantly enhanced. These cells acquire a pronounced ability to recognize and destroy tumor cells.
• The drug acts as an inducer, forcing the immune system to produce a number of other crucial cytokines. In particular, the synthesis of interferon-gamma (IFN-γ), tumor necrosis factor (TNF), and interleukin-1 is induced.

Due to such pronounced antitumor activity, the main clinical indication for prescribing aldesleukin is renal cell carcinoma.

Betaleukin: a hematopoietic and immune stimulant

The second important drug in this group is betaleukin. Its description states that it is human recombinant interleukin-1β. Unlike aldesleukin, the pharmacodynamics of betaleukin has a distinct dual focus, affecting both hematopoiesis and cellular immunity.

1. Hemostimulatory action. Betaleukin actively intervenes in hematopoietic processes. It activates the body's production of specific colony-stimulating factors. As a result of this cascade, the proliferation (multiplication) and differentiation (maturation) of cells belonging to various hematopoietic lineages are manifold enhanced.
2. Immunostimulatory action. The drug directly affects white blood cells, significantly increasing the functional activity of neutrophils and lymphocytes.

The main indication for betaleukin use is leukopenia (decreased white blood cell count in the blood). Most frequently, this condition is caused by aggressive medical intervention: courses of chemotherapy using cytostatics or exposure to ionizing radiation.

When prescribing betaleukin, the physician must consider potential side effects. Therapy may be accompanied by hyperthermia (elevated body temperature), severe chills, and headache.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Detailed mechanism of aldesleukin binding to IL-2 receptors
• The role of induced cytokines (IFN-γ, TNF, IL-1) in the immune response
• The relationship between betaleukin and colony-stimulating factors in hematopoiesis
• Pathogenesis of leukopenia development during cytostatic therapy and ionizing radiation
• Mechanisms of hyperthermia and chills development upon administration of recombinant cytokines

Other topics in the section "Agents Regulating Immune Processes"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.